This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Macular Degeneration  • Articles for Residents  • Alert me on articles by topic  Social Bookmarking   What's this?

AREDS Report No. 13

AREDS Research Group

Arch Ophthalmol. 2004;122:716-726.

Objective  To assess the association of ocular disorders and high doses of antioxidants or zinc with mortality in the Age-Related Eye Disease Study (AREDS).

Methods  Baseline fundus and lens photographs were used to grade the macular and lens status of AREDS participants. Participants were randomly assigned to receive oral supplements of high-dose antioxidants, zinc, antioxidants plus zinc, or placebo. Risk of all-cause and cause-specific mortality was assessed using adjusted Cox proportional hazards models.

Results  During median follow-up of 6.5 years, 534 (11%) of 4753 AREDS participants died. In fully adjusted models, participants with advanced age-related macular degeneration (AMD) compared with participants with few, if any, drusen had increased mortality (relative risk [RR], 1.41; 95% confidence interval [CI], 1.08-1.86). Advanced AMD was associated with cardiovascular deaths. Compared with participants having good acuity in both eyes, those with visual acuity worse than 20/40 in 1 eye had increased mortality (RR, 1.36; 95% CI, 1.12-1.65). Nuclear opacity (RR, 1.40; 95% CI, 1.12-1.75) and cataract surgery (RR, 1.55; 95% CI, 1.18-2.05) were associated with increased all-cause mortality and with cancer deaths. Participants randomly assigned to receive zinc had lower mortality than those not taking zinc (RR, 0.73; 95% CI, 0.61-0.89).

Conclusions  The decreased survival of AREDS participants with AMD and cataract suggests that these conditions may reflect systemic rather than only local processes. The improved survival in individuals randomly assigned to receive zinc requires further study.

The Writing Team for the AREDS Research Group is Traci E. Clemons, PhD; Natalie Kurinij, PhD; Robert D. Sperduto, MD; and Susan B. Bressler, MD. Other members of the AREDS Research Group are listed in a box above. The Writing Team members and the AREDS investigators have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Direct and Indirect Effects of Visual Impairment on Mortality Risk in Older Persons: The Blue Mountains Eye Study
Karpa et al.
Arch Ophthalmol 2009;127:1347-1353.
ABSTRACT | FULL TEXT  

Homocysteine Is Not So Paradoxical
Klevay
Arterioscler. Thromb. Vasc. Bio. 2008;28:e160-e160.
FULL TEXT  

Serum zinc and pneumonia in nursing home elderly
Meydani et al.
Am. J. Clin. Nutr. 2007;86:1167-1173.
ABSTRACT | FULL TEXT  

Age-Related Macular Degeneration and Cancer Mortality in the Atherosclerosis Risk in Communities Study
Cheung et al.
Arch Ophthalmol 2007;125:1241-1247.
ABSTRACT | FULL TEXT  

Visual Impairment, Age-Related Macular Degeneration, Cataract, and Long-term Mortality: The Blue Mountains Eye Study
Cugati et al.
Arch Ophthalmol 2007;125:917-924.
ABSTRACT | FULL TEXT  

Circulating Inflammatory Markers and Hemostatic Factors in Age-Related Maculopathy: A Population-Based Case-Control Study
Wu et al.
IOVS 2007;48:1983-1988.
ABSTRACT | FULL TEXT  

Zinc: Mechanisms of Host Defense
Prasad
J. Nutr. 2007;137:1345-1349.
ABSTRACT | FULL TEXT  

Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress
Prasad et al.
Am. J. Clin. Nutr. 2007;85:837-844.
ABSTRACT | FULL TEXT  

Relationship Between Age-Related Macular Degeneration-Associated Variants of Complement Factor H and LOC387715 With Coronary Artery Disease
Pulido et al.
Mayo Clin Proc. 2007;82:301-307.
ABSTRACT | FULL TEXT  

Heart Outcomes Prevention Evaluation-The Ongoing Outcomes Study, Vitamin E, and Age-Related Macular Degeneration--Reply
Chew and Clemons
Arch Ophthalmol 2006;124:1665-1666.
FULL TEXT  

Age-related eye disease, visual impairment, and survival: the beaver dam eye study.
Knudtson et al.
Arch Ophthalmol 2006;124:243-249.
ABSTRACT | FULL TEXT  

Prevalence of Age-Related Macular Degeneration in a Population-Based Sample of Hispanic People in Arizona: Proyecto VER
Munoz et al.
Arch Ophthalmol 2005;123:1575-1580.
ABSTRACT | FULL TEXT  

The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study
McGwin et al.
Br J Ophthalmol 2005;89:1166-1170.
ABSTRACT | FULL TEXT  

Vitamin E and the Age-Related Eye Disease Study Supplementation for Age-Related Macular Degeneration
Chew and Clemons
Arch Ophthalmol 2005;123:395-396.
FULL TEXT  

From the Library
Br J Ophthalmol 2004;88:1104-1104.
FULL TEXT